IG
Highly rated in
22
conditions
Highly rated in
22
conditions
Check Dr. Ivana N. Gojo's experience treating your condition:
About Dr. Ivana N. Gojo

Ivana Gojo is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Gojo has been practicing medicine for over 31 years and is highly rated in 22 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Maryland. Gojo is currently accepting new patients.

Her clinical research consists of co-authoring 89 peer reviewed articles and participating in 14 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Ivana N. Gojo it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Ivana N. Gojo accepts the following insurance:

  •  Ambetter
  •  CareFirst

Call to see if your plan is accepted.
Locations
Baltimore, MD 21231
Other Locations
1650 Orleans St, Baltimore, MD 21287
Background & Education
Graduate Institution
Other, 1992
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Howard County General Hospital
Languages Spoken
English
Croatian
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


14 Clinical Trials

A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
LCCC 1522: Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia
A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients
A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The Clinical Application of Tumor Reversion: A Phase I Study of Sertraline (Zoloft) in Combination With Timed-sequential Cytosine Arabinoside (Ara-C) in Adults With Relapsed and Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Study of UCN-01 in Combination With Perifosine in Patients With Relapsed and Refractory Acute Leukemias and High Risk MDS
View 11 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors